Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This study is conducted to evaluate the efficacy and safety of lenvatinib plus iodine-125
seed brachytherapy (Len-I) compared with lenvatinib (Len) alone for patients with
hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).
Phase:
Phase 3
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University